Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates

Table 4 Clinical features of the rtA181T mutant and rN236T groups n (%)

Clinical features	rtA181T mutant(n = 50)	rtN236T mutant(n = 7)	Statistical value	P-value
Gender (M/F)	43/7	7/0	χ2 = 0.069	0.792
Age (yr, mean ± SD)	42.6 ± 9.4	47.3 ± 12.1	t = 1.201	0.235
End-stage liver disease1	19 (38)	3 (42.86)	χ2 = 0.026	1.000
NAFLD	20 (40)	3 (42.86)	χ2 = 0.009	1.000
E-antigen (+/–)	25/25	2/5	χ2 = 1.131	0.427
Genotype (B/C)	7/43	5/2a	χ2 = 5.958	0.028
HBV-DNA (log10 copy/mL)	5.18 ± 1.23	4.91 ± 1.20	t = 0.544	0.588

¹End-stage liver disease: included hepatitis cirrhosis, liver failure, and primary hepatocellular carcinoma.

^aP < 0.05 genotype (B/C) in the rtA181T mutant group vs the rtN236T mutant group. NAFLD: Non-alcoholic fatty liver disease; HBV: Hepatitis B virus.